Skip to main content
Premium Trial:

Request an Annual Quote

Mirus Bio Wins $900K SBIR Grant to Develop miRNA Tech With Potential Dx Apps

NEW YORK (GenomeWeb News) — Mirus Bio has received a two-year, $900,000 Phase II Small Business Innovative Research grant to develop its microRNA-labeling technology for clinical research and “potential diagnostic applications,” the company said today.
 
The Madison, Wis.-based miRNA and siRNA transfection company said it will use the money to develop products that will study the link between miRNAs and undisclosed diseases that it will eventually “enable diagnostic testing for miRNAs as biomarkers for disease.”
 
Mirus said it will market products resulting from the research. The company currently sells a Label IT miRNA kit that is used in microarray analysis.
 
Mirus will conduct the work in collaboration with Gregory Tsongalis, director of molecular pathology at the Dartmouth Hitchcock Medical Center in Lebanon, NH, it said.
 
The grant came from the National Institute of General Medical Sciences.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.